Statistiche di base
| LEI | 5299005B0KKBVJ0B2156 |
| CIK | 835887 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Progenics Pharmaceuticals, Inc.
SEC Filings (Chronological Order)
Questa pagina fornisce un elenco completo e cronologico dei depositi SEC, esclusi i documenti di proprietà che forniamo altrove.
| February 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| July 2, 2020 |
15-12G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number: 000-23143 PROGENICS PHARMACEUTICALS, INC. (Exact name of registrant |
|
| June 23, 2020 |
PGNX / Progenics Pharmaceuticals, Inc. / Lantheus Holdings, Inc. - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1) Progenics Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.0013 per share (Title of Class of Securities) 743187106 (CUSIP Number) Michael P. Duffy Lantheus Holdings, Inc. 331 Treble Cove Road North Billerica, Massachusetts 01862 |
|
| June 22, 2020 |
S-8 POS As filed with the Securities and Exchange Commission on June 22, 2020 Registration No. |
|
| June 22, 2020 |
S-8 POS As filed with the Securities and Exchange Commission on June 22, 2020 Registration No. |
|
| June 22, 2020 |
Lantheus Completes Merger with Progenics EX-99.1 Exhibit 99.1 Lantheus Completes Merger with Progenics NORTH BILLERICA, Mass. and NEW YORK—(BUSINESS WIRE)—June 22, 2020—Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc. (“LMI”), a global leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products, today announced that it has co |
|
| June 22, 2020 |
POS AM As filed with the Securities and Exchange Commission on June 22, 2020 Registration No. |
|
| June 22, 2020 |
Amended and Restated Bylaws of Progenics, effective June 19, 2020. EX-3.2 Exhibit 3.2 PROGENICS PHARMACEUTICALS, INC. (THE “CORPORATION”) BY-LAWS (AMENDED AND RESTATED AS OF JUNE 19, 2020) ARTICLE I Meetings of Stockholders Section 1.1 Annual Meetings. The annual meeting of the stockholders for the election of directors and for the transaction of such other business as properly may come before such meeting shall be held each year on such date, and at such time an |
|
| June 22, 2020 |
S-8 POS As filed with the Securities and Exchange Commission on June 22, 2020 Registration No. |
|
| June 22, 2020 |
S-8 POS As filed with the Securities and Exchange Commission on June 22, 2020 Registration No. |
|
| June 22, 2020 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 19, 2020 Progenics Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-23143 13-3379479 (State or other jurisdiction of incorporation) (Comm |
|
| June 22, 2020 |
EX-3.1 Exhibit 3.1 FOURTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF PROGENICS PHARMACEUTICALS, INC. FIRST: The name of the Corporation (the “Corporation”) is Progenics Pharmaceuticals, Inc. SECOND: The registered office of the Corporation in the State of Delaware is located at 251 Little Falls Drive, Wilmington, DE 19808, and County of New Castle. The name of its registered agent in the |
|
| June 22, 2020 |
S-8 POS As filed with the Securities and Exchange Commission on June 22, 2020 Registration No. |
|
| June 22, 2020 |
S-8 POS As filed with the Securities and Exchange Commission on June 22, 2020 Registration No. |
|
| June 22, 2020 |
S-8 POS As filed with the Securities and Exchange Commission on June 22, 2020 Registration No. |
|
| June 17, 2020 |
Submission of Matters to a Vote of Security Holders 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16, 2020 Progenics Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-23143 13-3379479 (State or other jurisdiction of incorporation) (Comm |
|
| June 16, 2020 |
Financial Statements and Exhibits, Other Events, Submission of Matters to a Vote of Security Holders 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16, 2020 Progenics Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-23143 13-3379479 (State or other jurisdiction of incorporation) (Comm |
|
| June 16, 2020 |
Progenics Stockholders Approve Merger with Lantheus EX-99.1 Exhibit 99.1 Progenics Stockholders Approve Merger with Lantheus NEW YORK, NY, June 16, 2020 – Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) (“Progenics”), an oncology company developing innovative medicines and artificial intelligence to find, fight and follow cancer, announced that at a special meeting of its stockholders held earlier today, Progenics’ stockholders voted to approve its |
|
| June 11, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 5, 2020 Progenics Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-23143 13-3379479 (State or other jurisdiction of incorporation) (Commissio |
|
| June 8, 2020 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 8, 2020 Progenics Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-23143 13-3379479 (State or other jurisdiction of incorporation) (Commi |
|
| May 28, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 22, 2020 Progenics Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-23143 13-3379479 (State or other jurisdiction of incorporation) (Commissio |
|
| May 18, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 18, 2020 Progenics Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-23143 13-3379479 (State or other jurisdiction of incorporation) (Commissio |
|
| May 18, 2020 |
Exhibit 99.1 Progenics Pharmaceuticals, Inc. One World Trade Center 47th Floor, Suite J New York, New York 10007 (646) 975-2500 www.progenics.com Progenics to Present Results from the Phase 3 CONDOR Trial of PyLTM (18F-DCFPyL) in Prostate Cancer at the American Society of Clinical Oncology 2020 Virtual Scientific Program - Met Primary Endpoint with a Correct Localization Rate of 84.8–87.0% - - 63. |
|
| May 14, 2020 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitt |
|
| May 12, 2020 |
425 Filed by Lantheus Holdings, Inc. Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Progenics Pharmaceuticals, Inc. Commission File No.: 000 – 23143 The following is a slide deck relating to the proposed transaction involving Lantheus Holdings, Inc. and Progenics Pharmaceuticals, Inc. available at |
|
| May 7, 2020 |
PROGENICS PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2020 FINANCIAL RESULTS AND BUSINESS UPDATE Exhibit 99.1 Progenics Pharmaceuticals, Inc. One World Trade Center 47th Floor, Suite J New York, New York 10007 (646) 975-2500 www.progenics.com PROGENICS PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2020 FINANCIAL RESULTS AND BUSINESS UPDATE ● Pending Merger with Lantheus Holdings, Inc. for Combination of an Innovative Commercial Life Sciences Company with a Diversified Precision Diagnostics and Radi |
|
| May 7, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2020 Progenics Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-23143 13-3379479 (State or other jurisdiction of incorporation) (Commission |
|
| May 7, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-2 |
|
| May 7, 2020 |
425 Filed by Progenics Pharmaceuticals, Inc. Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Progenics Pharmaceuticals, Inc. Commission File No.: 000-23143 TRANSCRIPT The following is a transcript of the Progenics Pharmaceuticals, Inc. earnings call held on May 7, 2020 at 8:30 a.m. Eastern Time. Imp |
|
| April 23, 2020 |
PGNX / Progenics Pharmaceuticals, Inc. / Lantheus Holdings, Inc. - SC 13D Activist Investment SC 13D 1 d921313dsc13d.htm SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 Progenics Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.0013 per share (Title of Class of Securities) 743187106 (CUSIP Number) Michael P. Duffy Lantheus Holdings, Inc. 331 Treble Cove Road North Billerica, Massachusetts |
|
| April 15, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 6)1 Progenics Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.0013 per share (Title of Class of Securities) 743187106 (CUSIP Number) Step |
|
| April 14, 2020 |
PGNX / Progenics Pharmaceuticals, Inc. 425 - Merger Prospectus - 8-K 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 14, 2020 Progenics Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-23143 13-3379479 (State or other jurisdiction of incorporation) (Com |
|
| April 14, 2020 |
Velan Capital Agrees to Support Merger of Lantheus and Progenics EX-99.1 Exhibit 99.1 Velan Capital Agrees to Support Merger of Lantheus and Progenics NORTH BILLERICA, Mass. and New York, NY – April 14, 2020 – Lantheus Holdings, Inc. (NASDAQ: LNTH) (“Lantheus”), parent company of Lantheus Medical Imaging, Inc. (“LMI”), a leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products, and Progenics Pharmaceutica |
|
| April 14, 2020 |
Velan Capital Agrees to Support Merger of Lantheus and Progenics EX-99.1 Exhibit 99.1 Velan Capital Agrees to Support Merger of Lantheus and Progenics NORTH BILLERICA, Mass. and New York, NY – April 14, 2020 – Lantheus Holdings, Inc. (NASDAQ: LNTH) (“Lantheus”), parent company of Lantheus Medical Imaging, Inc. (“LMI”), a leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products, and Progenics Pharmaceutica |
|
| April 14, 2020 |
Velan Capital Agrees to Support Merger of Lantheus and Progenics EX-99.1 Exhibit 99.1 Velan Capital Agrees to Support Merger of Lantheus and Progenics NORTH BILLERICA, Mass. and New York, NY – April 14, 2020 – Lantheus Holdings, Inc. (NASDAQ: LNTH) (“Lantheus”), parent company of Lantheus Medical Imaging, Inc. (“LMI”), a leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products, and Progenics Pharmaceutica |
|
| April 14, 2020 |
Financial Statements and Exhibits, Other Events 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 14, 2020 Progenics Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-23143 13-3379479 (State or other jurisdiction of incorporation) (Com |
|
| April 14, 2020 |
EX-10.1 Exhibit 10.1 EXECUTION VERSION SUPPORT AGREEMENT This SUPPORT AGREEMENT, dated as of April 14, 2020 (this “Agreement”), is entered into by and between Lantheus Holdings, Inc., a corporation existing under the laws of Delaware (“Parent”), and the parties listed on Schedule A and Schedule B attached hereto (each, a “Stockholder” and, collectively, the “Stockholders”). Unless otherwise indica |
|
| April 14, 2020 |
LNTH / Lantheus Holdings, Inc. 425 - Merger Prospectus - 8-K 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 14, 2020 LANTHEUS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36569 35-2318913 (State or other jurisdiction (Commission (IRS Employer |
|
| April 9, 2020 |
Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned persons hereby agree to the joint filing on behalf of each of them of a statement on Schedule 13D (including amendments thereto) with respect to the Common Stock, par value $0.0013 per share of Progenics Pharmaceuticals, Inc. and further agree that |
|
| April 9, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 5)1 Progenics Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.0013 per share (Title of Class of Securities) 743187106 (CUSIP Number) Step |
|
| April 2, 2020 |
EX-99.1 Exhibit 99.1 Lantheus and Progenics Reschedule Their Respective Special Meetings of Stockholders for Proposed Merger NORTH BILLERICA, MA – April 2, 2020 – Lantheus Holdings, Inc. (NASDAQ: LNTH) (“Lantheus”), parent company of Lantheus Medical Imaging, Inc. (“LMI”), a leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products, and Proge |
|
| April 2, 2020 |
EX-99.1 Exhibit 99.1 Lantheus and Progenics Reschedule Their Respective Special Meetings of Stockholders for Proposed Merger NORTH BILLERICA, MA – April 2, 2020 – Lantheus Holdings, Inc. (NASDAQ: LNTH) (“Lantheus”), parent company of Lantheus Medical Imaging, Inc. (“LMI”), a leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products, and Proge |
|
| April 2, 2020 |
PGNX / Progenics Pharmaceuticals, Inc. 425 - Merger Prospectus - 8-K 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 2, 2020 Progenics Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-23143 13-3379479 (State or other jurisdiction of incorporation) (Comm |
|
| April 2, 2020 |
LNTH / Lantheus Holdings, Inc. 425 - Merger Prospectus - 8-K 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 2, 2020 LANTHEUS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36569 (Commission File Num |
|
| April 2, 2020 |
Financial Statements and Exhibits, Other Events 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 2, 2020 Progenics Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-23143 13-3379479 (State or other jurisdiction of incorporation) (Comm |
|
| April 2, 2020 |
EX-99.1 Exhibit 99.1 Lantheus and Progenics Reschedule Their Respective Special Meetings of Stockholders for Proposed Merger NORTH BILLERICA, MA – April 2, 2020 – Lantheus Holdings, Inc. (NASDAQ: LNTH) (“Lantheus”), parent company of Lantheus Medical Imaging, Inc. (“LMI”), a leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products, and Proge |
|
| April 1, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 27, 2020 Progenics Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-23143 13-3379479 (State or other jurisdiction of incorporation) (Commiss |
|
| March 19, 2020 |
PGNX / Progenics Pharmaceuticals, Inc. DEFM14A - - DEFM14A DEFM14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 16, 2020 |
Exhibit 10.1 Execution Version BRIDGE LOAN AGREEMENT dated as of March 15, 2020 between PROGENICS PHARMACEUTICALS, INC., as Borrower and LANTHEUS MEDICAL IMAGING, INC., as Lender Table of Contents Page Article I DEFINITIONS; CONSTRUCTION 1 Section 1.1 Definitions 1 Section 1.2 Other Definitional Provisions 7 Section 1.3 Accounting Terms and Principles 7 Article II AMOUNT AND TERMS OF THE LOAN 7 Se |
|
| March 16, 2020 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 15, 2020 Progenics Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-23143 13-3379479 (State or other jurisdiction of incorporation) (Commiss |
|
| March 13, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2020 Progenics Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-23143 13-3379479 (State or other jurisdiction of incorporation) (Commiss |
|
| March 13, 2020 |
Employment Offer Letter Agreement between the Registrant and Asha Das. Exhibit 10.48 Progenics Pharmaceuticals, Inc. 777 Old Saw Mill River Road Tarrytown, New York 10591 Fax: (914) 789-2817 (914) 789-2800 www.progenics.com November 6, 2018 [*] Re: Offer of Employment Dear Asha: This letter is to confirm our offer to you for the position of Chief Medical Officer (CMO) reporting to Mark Baker – Chief Executive Officer (CEO) with Progenics Pharmaceuticals, Inc. This po |
|
| March 13, 2020 |
Employment Offer Letter Agreement between the Registrant and Benedict Osorio. Exhibit 10.50 Progenics Pharmaceuticals, Inc. 777 Old Saw Mill River Road Tarrytown, New York 10591 Fax: (914) 789-2817 (914) 789-2800 www.progenics.com January 19, 2018 [*] Re: Offer of Employment Dear Ben: This letter is to confirm our offer to you for the position of Senior Vice President, Quality reporting to Mark Baker, CEO with Progenics Pharmaceuticals, Inc. This position includes the follo |
|
| March 13, 2020 |
Form of Retention Bonus Agreement Exhibit 10.55 Progenics Pharmaceuticals, Inc. One World Trade Center, 47th Floor Suite J New York, NY 10007 Phone: (646) 975-2500 Fax: (646) 707-3626 www.progenics.com October 11, 2019 [NAME] c/o Progenics Pharmaceuticals, Inc. One World Trade Center, 47th Floor New York, NY 10007 Re: Retention Bonus Agreement Dear [FIRST NAME]: As you may know, Progenics Pharmaceuticals, Inc. (the “Company”) has |
|
| March 13, 2020 |
Consulting Services Agreement, dated November 15, 2019, between the Registrant and David Mims. Exhibit 10.54 Progenics Pharmaceuticals, Inc. One World Trade Center 47th Floor, Suite J New York, New York 10007 (646) 975-2500 www.progenics.com CONSULTING SERVICES AGREEMENT PROGENICS CONTRACT NO. 000000 This Consulting Services Agreement (“Agreement”) effective as of the November 15, 2019 (“Effective Date”) is by and between Progenics Pharmaceuticals, Inc., a corporation organized under the la |
|
| March 13, 2020 |
Subsidiaries of the Registrant. Exhibit 21.1 Progenics Pharmaceuticals, Inc. Subsidiaries Name Jurisdiction of Incorporation Excelsior Life Sciences Ireland Limited Ireland Molecular Insight Pharmaceuticals, Inc. Delaware Molecular Insight Limited* England and Wales Progenics Life Sciences Limited England and Wales Progenics Pharmaceuticals Nevada, Inc. Nevada PSMA Development Company LLC Delaware EXINI Diagnostics AB Sweden MNT |
|
| March 13, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-23143 |
|
| March 13, 2020 |
PROGENICS PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2019 FINANCIAL RESULTS Exhibit 99.1 Progenics Pharmaceuticals, Inc. One World Trade Center 47th Floor, Suite J New York, New York 10007 (646) 975-2500 www.progenics.com PROGENICS PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2019 FINANCIAL RESULTS NEW YORK, March 13, 2020 - Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) today announced financial results for the fourth quarter and full-year 2019. “The recent posi |
|
| March 13, 2020 |
PGNX / Progenics Pharmaceuticals, Inc. 425 - Merger Prospectus - FORM 425 Filed by Progenics Pharmaceuticals, Inc. Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Progenics Pharmaceuticals, Inc. Commission File No.: 000-23143 On March 13, 2020, Progenics Pharmaceuticals, Inc. issued the following press release: Progenics Pharmaceuticals, Inc. One World Trade Center 47th F |
|
| March 13, 2020 |
Employment Offer Letter Agreement between the Registrant and Bryce Tenbarge. Exhibit 10.51 Progenics Pharmaceuticals, Inc. 777 Old Saw Mill River Road Tarrytown, New York 10591 Fax: (914) 789-2817 (914) 789-2800 www.progenics.com August 2, 2016 [*] Re: Offer of Employment Dear Bryce: This letter is to confirm our offer to you for the position of Vice President, Commercial reporting to Mark Baker, Chief Executive Officer. This position includes the following compensation an |
|
| March 13, 2020 |
Exhibit 4.2 DESCRIPTION OF CAPITAL STOCK The following is a general summary of our common stock and preferred stock, certain provisions of our amended and restated certificate of incorporation (“certificate of incorporation”) and our amended and restated bylaws (“bylaws”), and applicable law. This summary does not purport to be complete and is qualified in its entirety by the provisions of our cer |
|
| March 4, 2020 |
Exhibit 10.1 Progenics Pharmaceuticals, Inc. One World Trade Center, 47th Floor, Suite J New York, NY 10007 Phone: (646) 975-2500 Fax: (646) 707-3626 www.progenics.com CONSULTING SERVICES AGREEMENT March 4, 2020 This Consulting Services Agreement (“Agreement”), effective as of March 27, 2020 (“Effective Date”) is by and between Progenics Pharmaceuticals, Inc., a corporation organized under the law |
|
| March 4, 2020 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2020 Progenics Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-23143 13-3379479 (State or other jurisdiction of incorporation) (Comm |
|
| February 27, 2020 |
LNTH / Lantheus Holdings, Inc. 425 - Merger Prospectus - 425 425 Filed by Lantheus Holdings, Inc. Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Progenics Pharmaceuticals, Inc. Commission File No.: 000 – 23143 The following are excerpts from the transcript for Lantheus Holdings, Inc.’s presentation at the SVB Leerink 9th Annual Global Healthcare Conference o |
|
| February 26, 2020 |
Filed by Lantheus Holdings, Inc. Filed by Lantheus Holdings, Inc. Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Progenics Pharmaceuticals, Inc. Commission File No.: 000 – 23143 On February 26, 2020, Lantheus Holdings, Inc. presented the following slides at the SVB Leerink 9th Annual Global Healthcare Conference. Safe Harbor State |
|
| February 21, 2020 |
Filed by Lantheus Holdings, Inc. Filed by Lantheus Holdings, Inc. Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Progenics Pharmaceuticals, Inc. Commission File No.: 000 ? 23143 The following is a slide deck relating to the proposed transaction involving Lantheus Holdings, Inc. and Progenics Pharmaceuticals, Inc. available at www. |
|
| February 20, 2020 |
Exhibit 99.1 Lantheus and Progenics Agree to Amended Transaction Terms Combination to Create Robust Portfolio and Pipeline of Precision Diagnostic and Therapeutic Products Progenics Shareholders Will Receive 0.31 Shares of Lantheus Common Stock for Each Share of Progenics Stock in All-Stock Transaction, Represents Approximately 40% Ownership Stake in Combined Company Progenics Shareholders Will Al |
|
| February 20, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 20, 2020 Progenics Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-23143 13-3379479 (State or other jurisdiction of incorporation) (Comm |
|
| February 20, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 20, 2020 LANTHEUS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36569 35-2318913 (State or other jurisdiction (Commission (IRS Employer o |
|
| February 20, 2020 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 20, 2020 Progenics Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-23143 13-3379479 (State or other jurisdiction of incorporation) (Comm |
|
| February 20, 2020 |
Exhibit 99.1 Lantheus and Progenics Agree to Amended Transaction Terms Combination to Create Robust Portfolio and Pipeline of Precision Diagnostic and Therapeutic Products Progenics Shareholders Will Receive 0.31 Shares of Lantheus Common Stock for Each Share of Progenics Stock in All-Stock Transaction, Represents Approximately 40% Ownership Stake in Combined Company Progenics Shareholders Will Al |
|
| February 20, 2020 |
Exhibit 2.1 AMENDED AND RESTATED AGREEMENT AND PLAN OF MERGER AMONG LANTHEUS HOLDINGS, INC., PLATO MERGER SUB, INC. AND PROGENICS PHARMACEUTICALS, INC. DATED AS OF FEBRUARY 20, 2020 Table of Contents Page Article I Defined Terms 2 Section 1.1 Certain Defined Terms 2 Article II The Merger 14 Section 2.1 The Merger 14 Section 2.2 Closing 15 Section 2.3 Effective Time 15 Section 2.4 Surviving Corpora |
|
| February 20, 2020 |
Exhibit 2.1 Execution Version AMENDED AND RESTATED AGREEMENT AND PLAN OF MERGER AMONG LANTHEUS HOLDINGS, INC., PLATO MERGER SUB, INC. AND PROGENICS PHARMACEUTICALS, INC. DATED AS OF FEBRUARY 20, 2020 Table of Contents Page Article I Defined Terms 2 Section 1.1 Certain Defined Terms 2 Article II The Merger 14 Section 2.1 The Merger 14 Section 2.2 Closing 15 Section 2.3 Effective Time 15 Section 2.4 |
|
| February 20, 2020 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 20, 2020 Progenics Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-23143 13-3379479 (State or other jurisdiction of incorporation) (Comm |
|
| February 20, 2020 |
Exhibit 99.1 Lantheus and Progenics Agree to Amended Transaction Terms Combination to Create Robust Portfolio and Pipeline of Precision Diagnostic and Therapeutic Products Progenics Shareholders Will Receive 0.31 Shares of Lantheus Common Stock for Each Share of Progenics Stock in All-Stock Transaction, Represents Approximately 40% Ownership Stake in Combined Company Progenics Shareholders Will Al |
|
| February 20, 2020 |
Exhibit 2.1 Execution Version AMENDED AND RESTATED AGREEMENT AND PLAN OF MERGER AMONG LANTHEUS HOLDINGS, INC., PLATO MERGER SUB, INC. AND PROGENICS PHARMACEUTICALS, INC. DATED AS OF FEBRUARY 20, 2020 Table of Contents Page Article I Defined Terms 2 Section 1.1 Certain Defined Terms 2 Article II The Merger 14 Section 2.1 The Merger 14 Section 2.2 Closing 15 Section 2.3 Effective Time 15 Section 2.4 |
|
| February 20, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 20, 2020 LANTHEUS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36569 35-2318913 (State or other jurisdiction of incorporation) (Commissi |
|
| February 20, 2020 |
Filed by Progenics Pharmaceuticals, Inc. Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Progenics Pharmaceuticals, Inc. Commission File No.: 000 - 23143 About Lantheus Holdings, Inc. and Lantheus Medical Imaging, Inc. PGNX Renegotiated Transaction Investor / Analyst Talking Points What We Announced |
|
| February 20, 2020 |
Form of Contingent Value Rights Agreement Exhibit 10.1 Form of Contingent Value Rights Agreement between Lantheus Holdings, Inc. and [?] as Rights Agent Dated as of [?], 2020 Table of Contents Page ARTICLE I DEFINITIONS; INTERPRETATION 1 Section 1.01 Definitions 1 Section 1.02 Interpretation 3 ARTICLE II CONTINGENT VALUE RIGHTS 5 Section 2.01 Holders of CVRs; Appointment of Rights Agent 5 Section 2.02 Nontransferable 6 Section 2.03 No Cer |
|
| February 20, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 20, 2020 Progenics Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-23143 13-3379479 (State or other jurisdiction of incorporation) (Comm |
|
| February 14, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 14, 2020 |
PGNX / Progenics Pharmaceuticals, Inc. / ARMISTICE CAPITAL, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 11, 2020 |
PGNX / Progenics Pharmaceuticals, Inc. / VANGUARD GROUP INC - SCHEDULE 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: Progenics Pharmaceuticals Inc Title of Class of Securities: Common Stock CUSIP Number: 743187106 Date of Event Which Requires Filing of this Statement: December 31, 2019 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13d- |
|
| January 21, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 21, 2020 Progenics Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-23143 13-3379479 (State or other jurisdiction of incorporation) (Commi |
|
| January 21, 2020 |
Progenics Pharmaceuticals Provides Update on Reconstituted Board’s Ongoing Strategic Review Exhibit 99.1 Progenics Pharmaceuticals, Inc. One World Trade Center 47th Floor, Suite J New York, New York 10007 (646) 975-2500 www.progenics.com Progenics Pharmaceuticals Provides Update on Reconstituted Board’s Ongoing Strategic Review NEW YORK, NY, January 21, 2020 – The Board of Directors of Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative targeted medic |
|
| January 10, 2020 |
LNTH / Lantheus Holdings, Inc. 425 - Merger Prospectus - 425 425 Filed by Lantheus Holdings, Inc. Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Progenics Pharmaceuticals, Inc. Commission File No.: 000 – 23143 Lantheus Holdings, Inc. provided the following list of talking points to certain of its employees on January 10, 2020. Lantheus products and corporate |
|
| January 8, 2020 |
LNTH / Lantheus Holdings, Inc. 425 - Merger Prospectus - 425 425 Filed by Lantheus Holdings, Inc. Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Progenics Pharmaceuticals, Inc. Commission File No.: 000 – 23143 On January 8, 2020, Lantheus Holdings, Inc. made available the following slides to its investors. Safe Harbor Statements Important Information For Inv |
|
| December 23, 2019 |
Exhibit 99.1 Progenics Pharmaceuticals, Inc. One World Trade Center 47th Floor, Suite J New York, New York 10007 (646) 975-2500 www.progenics.com Progenics Pharmaceuticals Announces Phase 3 CONDOR Trial of PyLTM in Prostate Cancer Achieved Primary Endpoint - Met Primary Endpoint With a Correct Localization Rate of 84.8–87.0%, Highlighting Strong Diagnostic Performance - Company Expects to Submit a |
|
| December 23, 2019 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 23, 2019 Progenics Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-23143 13-3379479 (State or other jurisdiction of incorporation) (Comm |
|
| December 19, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 13, 2019 Progenics Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-23143 13-3379479 (State or other jurisdiction of incorporation) (Comm |
|
| November 21, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 15, 2019 Progenics Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-23143 13-3379479 (State or other jurisdiction of incorporation) (Comm |
|
| November 21, 2019 |
Progenics Pharmaceuticals Appoints David Mims as Interim Chief Executive Officer Exhibit 99.1 Progenics Pharmaceuticals, Inc. One World Trade Center 47th Floor, Suite J New York, New York 10007 (646) 975-2500 www.progenics.com Progenics Pharmaceuticals Appoints David Mims as Interim Chief Executive Officer NEW YORK, NY, November 21, 2019 – Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to |
|
| November 15, 2019 |
Amended and Restated Bylaws of Progenics Pharmaceuticals, Inc., effective November 8, 2019 Exhibit 3.1 BY-LAWS of PROGENICS PHARMACEUTICALS, INC. a Delaware corporation (Amended and restated as of November 8, 2019) Article I - OFFICES Section 1.01 Registered Office. The registered office of the Corporation shall be located in the City of Dover, County of Kent, State of Delaware. Section 1.02 Other Offices. The Corporation may also have offices at such other places, within or without the |
|
| November 15, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2019 Progenics Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-23143 13-3379479 (State or other jurisdiction of incorporation) (Commi |
|
| November 13, 2019 |
LNTH / Lantheus Holdings, Inc. 425 - Merger Prospectus - 425 425 Filed by Lantheus Holdings, Inc. Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Progenics Pharmaceuticals, Inc. Commission File No.: 000 – 23143 The following is a slide deck relating to the proposed transaction involving Lantheus Holdings, Inc. and Progenics Pharmaceuticals, Inc. available at |
|
| November 12, 2019 |
8-K 1 prog201911118k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 11, 2019 Progenics Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-23143 13-3379479 (State or other ju |
|
| November 12, 2019 |
Exhibit 99.2 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned persons hereby agree to the joint filing on behalf of each of them of a statement on Schedule 13D (including amendments thereto) with respect to the Common Stock, par value $0.0013 per share of Progenics Pharmaceuticals, Inc. and further agree that |
|
| November 12, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 4)1 Progenics Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.0013 per share (Title of Class of Securities) 743187106 (CUSIP Number) Step |
|
| November 12, 2019 |
TERMINATION OF Joint Filing and Solicitation Agreement November 12, 2019 Exhibit 99.1 TERMINATION OF Joint Filing and Solicitation Agreement November 12, 2019 Each of the undersigned is a party to that certain Joint Filing and Solicitation Agreement, dated September 18, 2019 (the “Joint Filing and Solicitation Agreement”). Each of the undersigned hereby agrees that the Joint Filing and Solicitation Agreement is terminated effective immediately. [Signature page follows] |
|
| November 8, 2019 |
PGNX / Progenics Pharmaceuticals, Inc. DEFA14A - - FORM DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| November 8, 2019 |
PGNX / Progenics Pharmaceuticals, Inc. DFAN14A - - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of The Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide |
|
| November 7, 2019 |
PGNX / Progenics Pharmaceuticals, Inc. 425 - Merger Prospectus - FORM 425 Filed by Progenics Pharmaceuticals, Inc. Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed pursuant to Rule 14a-6 of the Securities Exchange Act of 1934 Subject Company: Progenics Pharmaceuticals, Inc. Commission File No.: 000 - 23143 The following are excerpts from the press release issued by Progenics Pharmaceuticals, Inc. on November 7, 2019: […] ● Lantheus Holdings, Inc. to A |
|
| November 7, 2019 |
Exhibit 10.5 NON-QUALIFIED STOCK OPTION AWARD AGREEMENT Progenics Pharmaceuticals, Inc. 2018 Performance Incentive Plan – Grant #NUMBER This Award Agreement (the “Agreement”) made as of this DATE, between Progenics Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and NAME (the “Optionee”), is made pursuant to the terms of the Progenics Pharmaceuticals, Inc. 2018 Performance Incentive |
|
| November 7, 2019 |
Amended and Restated By-laws of the Registrant. Exhibit 3.2 AMENDED AND RESTATED BY-LAWS of PROGENICS PHARMACEUTICALS, INC. a Delaware corporation (Amended and restated as of APRILas AMENDED OCTOBER 1, 2019) PROGENICS PHARMACEUTICALS, INC. (a Delaware corporation) BY-LAWS Article I - OFFICES Section 1.01 Registered Office. The registered office of the Corporation shall be located in the City of Dover, County of Kent, State of Delaware. Section |
|
| November 7, 2019 |
Exhibit 10.6 NON-QUALIFIED STOCK OPTION AWARD AGREEMENT Progenics Pharmaceuticals, Inc. 2018 Performance Incentive Plan – Grant #NUMBER This Award Agreement (the “Agreement”) made as of this DATE, between Progenics Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and NAME (the “Optionee”), is made pursuant to the terms of the Progenics Pharmaceuticals, Inc. 2018 Performance Incentive |
|
| November 7, 2019 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 0 |
|
| November 7, 2019 |
LNTH / Lantheus Holdings, Inc. 425 - Merger Prospectus - 425 425 Filed by Lantheus Holdings, Inc. Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Progenics Pharmaceuticals, Inc. Commission File No.: 000 – 23143 The following is a slide deck relating to the proposed transaction involving Lantheus Holdings, Inc. and Progenics Pharmaceuticals, Inc. available at |
|
| November 7, 2019 |
EX-99.1 Exhibit 99.1 Lantheus Releases Comprehensive Strategic Plan for Progenics Lantheus’ Value-Creating Vision for Integrating and Executing Transaction is Best Path Forward for Progenics Lantheus’ In-Place Infrastructure and Commercial Capabilities Will Ensure the Progress of AZEDRA, and the PyL and 1095 Programs NORTH BILLERICA, Mass. – November 7, 2019 – Lantheus Holdings, Inc. (“Lantheus” o |
|
| November 7, 2019 |
LNTH / Lantheus Holdings, Inc. 425 - Merger Prospectus - 8-K 425 1 d805232d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2019 LANTHEUS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36569 35-2318913 (State or other jurisdiction of |
|
| November 7, 2019 |
PROGENICS PHARMACEUTICALS ANNOUNCES BUSINESS UPDATE AND THIRD QUARTER 2019 FINANCIAL RESULTS EX-99.1 2 ex163299.htm EXHIBIT 99.1 Exhibit 99.1 Progenics Pharmaceuticals, Inc. One World Trade Center 47th Floor, Suite J New York, New York 10007 (646) 975-2500 www.progenics.com PROGENICS PHARMACEUTICALS ANNOUNCES BUSINESS UPDATE AND THIRD QUARTER 2019 FINANCIAL RESULTS ● Lantheus Holdings, Inc. to Acquire Progenics to Form an Innovative Commercial Life Sciences Company with a Diversified Port |
|
| November 7, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2019 Progenics Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-23143 13-3379479 (State or other jurisdiction of incorporation) (Commi |
|
| November 6, 2019 |
PGNX / Progenics Pharmaceuticals, Inc. DEFA14A - - FORM DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| November 6, 2019 |
PGNX / Progenics Pharmaceuticals, Inc. 425 - Merger Prospectus - FORM 425 Filed by Progenics Pharmaceuticals, Inc. Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed pursuant to Rule 14a-6 of the Securities Exchange Act of 1934 Subject Company: Progenics Pharmaceuticals, Inc. Commission File No.: 000 - 23143 On November 6, 2019, Progenics Pharmaceuticals, Inc. issued the following press release: Progenics Reminds Shareholders that November 17 is the Tru |
|
| November 6, 2019 |
PGNX / Progenics Pharmaceuticals, Inc. CORRESP - - O’Melveny & Myers LLP Times Square Tower Seven Times Square New York, NY 10036 T: +1 212 326 2000 F: +1 212 326 2061 omm. |
|
| November 5, 2019 |
PGNX / Progenics Pharmaceuticals, Inc. DFAN14A - - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of The Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide |
|
| November 5, 2019 |
PGNX / Progenics Pharmaceuticals, Inc. DEFA14A - - FORM DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| November 5, 2019 |
PGNX / Progenics Pharmaceuticals, Inc. 425 - Merger Prospectus - FORM 425 425 1 prog20191104425.htm FORM 425 Filed by Progenics Pharmaceuticals, Inc. Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed pursuant to Rule 14a-6 of the Securities Exchange Act of 1934 Subject Company: Progenics Pharmaceuticals, Inc. Commission File No.: 000 - 23143 On November 4, 2019, Progenics Pharmaceuticals, Inc. issued the following press release disclosing a letter it i |
|
| November 4, 2019 |
PGNX / Progenics Pharmaceuticals, Inc. DFAN14A - - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of The Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide |
|
| November 1, 2019 |
PGNX / Progenics Pharmaceuticals, Inc. 425 - Merger Prospectus - FORM 425 Filed by Progenics Pharmaceuticals, Inc. Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed pursuant to Rule 14a-6 of the Securities Exchange Act of 1934 Subject Company: Progenics Pharmaceuticals, Inc. Commission File No.: 000 - 23143 On November 1, 2019, Progenics Pharmaceuticals, Inc. issued the following press release disclosing a letter it intends to mail to its shareholders: |
|
| November 1, 2019 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 31, 2019 Progenics Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-23143 13-3379479 (State or other jurisdiction of incorporation) (Commi |
|
| November 1, 2019 |
Slide to Progenics Pharmaceuticals, Inc. Presentation Exhibit 99.1 |
|
| November 1, 2019 |
PGNX / Progenics Pharmaceuticals, Inc. 425 - Merger Prospectus - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 31, 2019 Progenics Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-23143 13-3379479 (State or other jurisdiction of incorporation) (Commi |
|
| November 1, 2019 |
Slide to Progenics Pharmaceuticals, Inc. Presentation Exhibit 99.1 |
|
| November 1, 2019 |
LNTH / Lantheus Holdings, Inc. 425 - Merger Prospectus - 425 425 1 d826873d425.htm 425 Filed by Lantheus Holdings, Inc. Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Progenics Pharmaceuticals, Inc. Commission File No.: 000 – 23143 The following are excerpts from the transcript for the earnings call held by Lantheus Holdings, Inc. for the quarter ended Septe |
|
| October 29, 2019 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 29, 2019 Progenics Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-23143 13-3379479 (State or other jurisdiction of incorporation) (Commi |
|
| October 29, 2019 |
Presentation to Glass, Lewis & Co. Exhibit 99.1 |
|
| October 29, 2019 |
Presentation to Glass, Lewis & Co. Exhibit 99.1 |
|
| October 29, 2019 |
PGNX / Progenics Pharmaceuticals, Inc. 425 - Merger Prospectus - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 29, 2019 Progenics Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-23143 13-3379479 (State or other jurisdiction of incorporation) (Commi |
|
| October 28, 2019 |
PGNX / Progenics Pharmaceuticals, Inc. 425 - Merger Prospectus - FORM 425 Filed by Progenics Pharmaceuticals, Inc. Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed pursuant to Rule 14a-6 of the Securities Exchange Act of 1934 Subject Company: Progenics Pharmaceuticals, Inc. Commission File No.: 000 - 23143 On October 28, 2019, Progenics Pharmaceuticals, Inc. issued the following press release in response to a report issued by Institutional Shareholder |
|
| October 28, 2019 |
PGNX / Progenics Pharmaceuticals, Inc. DFAN14A - - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of The Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide |
|
| October 24, 2019 |
PGNX / Progenics Pharmaceuticals, Inc. DFAN14A - - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of The Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide |
|
| October 23, 2019 |
PGNX / Progenics Pharmaceuticals, Inc. DFAN14A - - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of The Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide |
|
| October 23, 2019 |
Exhibit 99.1 |
|
| October 23, 2019 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 23, 2019 Progenics Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-23143 13-3379479 (State or other jurisdiction of incorporation) (Commi |
|
| October 23, 2019 |
Exhibit 99.1 |
|
| October 23, 2019 |
PGNX / Progenics Pharmaceuticals, Inc. 425 - Merger Prospectus - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 23, 2019 Progenics Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-23143 13-3379479 (State or other jurisdiction of incorporation) (Commi |
|
| October 23, 2019 |
PGNX / Progenics Pharmaceuticals, Inc. 425 - Merger Prospectus - FORM 425 Filed by Progenics Pharmaceuticals, Inc. Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed pursuant to Rule 14a-6 of the Securities Exchange Act of 1934 Subject Company: Progenics Pharmaceuticals, Inc. Commission File No.: 000 - 23143 On October 23, 2019, Progenics Pharmaceuticals, Inc. issued the following press release disclosing a letter it intends to mail to its shareholders: |
|
| October 23, 2019 |
LNTH / Lantheus Holdings, Inc. 425 - Merger Prospectus - 425 425 Filed by Lantheus Holdings, Inc. Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Progenics Pharmaceuticals, Inc. Commission File No.: 000 – 23143 The following is a document relating to the proposed transaction involving Lantheus Holdings, Inc. and Progenics Pharmaceuticals, Inc. available at ww |
|
| October 22, 2019 |
PGNX / Progenics Pharmaceuticals, Inc. DFAN14A - - EXHIBIT 1 begin 644 ex1todfan14a12274002102219.pdf M)5!$1BTQ+C4-)>+CS],-"C,T(# @;V)J#3P\+TQI;F5A!C0 ^H P+$')L8!!8.$':@('A7TC) MM@P&!L;59^56RX$(CHZ&C@ZF#H:.#K8.N!*P5H8C1R T S8L# &'LXKP8XE M]BXNT=;&^\V9ZA8]3F7@>2/F )8&*CI6!Z09@;@+B(48&*ZNAO 9M0$"# "L MQ1^U#0IE;F1S=')E86T-96YD;V)J#3,U(# @;V)J#3P\+TUE=&%D871A(#$V M(# @4B]086=E3&%B96QS(#,P(# @4B]086=E%LP(# @-C$R(#%LP M(# @-C$R(#P,@E@CO$\XCPH9/$E=#YQ L]X@7$]R6()/ |
|
| October 22, 2019 |
PGNX / Progenics Pharmaceuticals, Inc. DFAN14A - - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of The Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide |
|
| October 21, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 21, 2019 Progenics Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-23143 13-3379479 (State or other jurisdiction of incorporation) (Commi |
|
| October 21, 2019 |
Presentation to Institutional Shareholder Services Inc. Exhibit 99.1 |
|
| October 21, 2019 |
PGNX / Progenics Pharmaceuticals, Inc. 425 - Merger Prospectus - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 21, 2019 Progenics Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-23143 13-3379479 (State or other jurisdiction of incorporation) (Commi |
|
| October 21, 2019 |
Presentation to Institutional Shareholder Services Inc. Exhibit 99.1 |
|
| October 21, 2019 |
PGNX / Progenics Pharmaceuticals, Inc. 425 - Merger Prospectus - FORM 425 Filed by Progenics Pharmaceuticals, Inc. Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed pursuant to Rule 14a-6 of the Securities Exchange Act of 1934 Subject Company: Progenics Pharmaceuticals, Inc. Commission File No.: 000 - 23143 On October 21, 2019, Progenics Pharmaceuticals, Inc. issued the following press release disclosing a letter it intends to mail to its shareholders: |
|
| October 21, 2019 |
PGNX / Progenics Pharmaceuticals, Inc. DFAN14A - - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of The Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide |
|
| October 21, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of The Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide |
|
| October 21, 2019 | ||
| October 18, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 11, 2019 Progenics Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-23143 13-3379479 (State or other jurisdiction of incorporation) (Commi |
|
| October 16, 2019 |
PGNX / Progenics Pharmaceuticals, Inc. DFAN14A - - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of The Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide |
|
| October 11, 2019 |
PGNX / Progenics Pharmaceuticals, Inc. DFRN14A - - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN CONSENT STATEMENT SCHEDULE 14A INFORMATION Consent Statement Pursuant to Section 14(a) of The Securities Exchange Act of 1934 Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Consent Statement ☐ Confidential, for |
|
| October 10, 2019 |
PGNX / Progenics Pharmaceuticals, Inc. 425 - Merger Prospectus - FORM 425 425 1 prog20191009425.htm FORM 425 Filed by Progenics Pharmaceuticals, Inc. Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Progenics Pharmaceuticals, Inc. Commission File No.: 000 - 23143 On October 9, 2019, Progenics Pharmaceuticals, Inc. issued the following press release disclosing a letter it i |
|
| October 8, 2019 |
PGNX / Progenics Pharmaceuticals, Inc. DEFC14A - - FORM DEFC14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Consent Revocation Statement Pursuant To Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Consent Revocation Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Consent Revocation Statement ☐ Definitive Additional Materials ☐ Soliciting Material under §240. |
|
| October 8, 2019 |
begin 644 ex1todfan14a12274002100819.pdf M)5!$1BTQ+C<-)>+CS],-"C0X(# @;V)J#3P\+TQI;F5A 9,0$4DP>0E$ M,A\'DHP[7P/)V(B#$Q 6:#369@I +Y'VCT%X P!VKPXM#0IE;F1S=')E M86T-96YD;V)J#7-T87)T>')E9@T*, T*)25%3T8-"B @(" @(" @( T*-S@@ M,"!O8FH-/#PO1FEL=&5R+T9L871E1&5C;V1E+TD@,38V+TQE;F=T:" Q-3(O M4R Q,#(^/G-TQDT&A@Z&)@R.H!R M'0QL'<>2P<3+J,H@Z-!Q1L M#]KNV\"PETV784D#Q#5B#!SKE8 T(Q!Q 08 .&))7!E+T-A=&%L;V<^/@UE;F1O8F |
|
| October 8, 2019 |
PGNX / Progenics Pharmaceuticals, Inc. DFAN14A - - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of The Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide |
|
| October 7, 2019 |
PGNX / Progenics Pharmaceuticals, Inc. DEFC14A - - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN CONSENT STATEMENT SCHEDULE 14A INFORMATION Consent Statement Pursuant to Section 14(a) of The Securities Exchange Act of 1934 Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Consent Statement ☐ Confidential, for |
|
| October 4, 2019 |
PGNX / Progenics Pharmaceuticals, Inc. PRER14A - - FORM PRER14A PRER14A 1 prog20191004prer14a.htm FORM PRER14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Consent Revocation Statement Pursuant To Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Consent Revocation Statement |
|
| October 4, 2019 |
LNTH / Lantheus Holdings, Inc. 425 - Merger Prospectus - 425 425 1 d812199d425.htm 425 Filed by Lantheus Holdings, Inc. Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Progenics Pharmaceuticals, Inc. Commission File No.: 000 – 23143 The following is a slide deck relating to the proposed transaction involving Lantheus Holdings, Inc. and Progenics Pharmaceutica |
|
| October 4, 2019 |
LNTH / Lantheus Holdings, Inc. 425 - Merger Prospectus - 425 425 1 d812199d425.htm 425 Filed by Lantheus Holdings, Inc. Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Progenics Pharmaceuticals, Inc. Commission File No.: 000 - 23143 The following communication is being filed in connection with the proposed transaction involving Lantheus Holdings, Inc. and Pro |
|
| October 4, 2019 |
PGNX / Progenics Pharmaceuticals, Inc. CORRESP - - O’Melveny & Myers LLP T: +1 212 326 2000 Times Square Tower F: +1 212 326 2061 Seven Times Square omm. |
|
| October 3, 2019 |
PGNX / Progenics Pharmaceuticals, Inc. PRRN14A - - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN CONSENT STATEMENT SCHEDULE 14A INFORMATION Consent Statement Pursuant to Section 14(a) of The Securities Exchange Act of 1934 (Amendment No. 2) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☒ Preliminary Consent Statement ☐ |
|
| October 2, 2019 |
PGNX / Progenics Pharmaceuticals, Inc. 425 - Merger Prospectus - 425 425 1 d784166d425.htm 425 Filed by Progenics Pharmaceuticals, Inc. Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Progenics Pharmaceuticals, Inc. Commission File No.: 000 - 23143 The following are screenshots of a website relating to the proposed transaction involving Lantheus Holdings, Inc. and Pr |
|
| October 2, 2019 |
LNTH / Lantheus Holdings, Inc. 425 - Merger Prospectus - 425 (#1) 425 (#1) Filed by Lantheus Holdings, Inc. Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Progenics Pharmaceuticals, Inc. Commission File No.: 000 - 23143 LMI ALL EMPLOYEE NOTE Team, I wish I could be with you personally to share this great news. Today, we announced that Lantheus has entered into an |
|
| October 2, 2019 |
EX-99.1 Exhibit 99.1 Lantheus to Acquire Progenics to Form a Leading Precision Diagnostics Imaging and Therapeutics Company Highly Complementary Portfolio of Ultrasound and Radiopharmaceutical Diagnostics and Oncology Therapeutics Lantheus’ Proven Commercial, Manufacturing and Operational Excellence Well Positioned to Optimize the Combined Company’s Innovative Diagnostic and Radiopharmaceutical Po |
|
| October 2, 2019 |
Amendment to the Bylaws of Progenics Pharmaceuticals, Inc. EX-3.2 Exhibit 3.2 AMENDMENT NO. 1 OF BY-LAWS OF PROGENICS PHARMACEUTICALS, INC. A DELAWARE CORPORATION (AMENDED AND RESTATED AS OF APRIL 1, 2019) October 1, 2019 The undersigned, the duly acting Secretary of the corporation, hereby certifies that: 1. The undersigned is the duly acting Secretary of PROGENICS PHARMACEUTICALS, INC., a Delaware corporation (the “corporation”). 2. Pursuant to a resolu |
|
| October 2, 2019 |
EX-2.1 Exhibit 2.1 Execution Version AGREEMENT AND PLAN OF MERGER AMONG LANTHEUS HOLDINGS, INC., PLATO MERGER SUB, INC. AND PROGENICS PHARMACEUTICALS, INC. DATED AS OF OCTOBER 1, 2019 Table of Contents Page Article I Defined Terms 2 Section 1.1 Certain Defined Terms 2 Article II The Merger 13 Section 2.1 The Merger 13 Section 2.2 Closing 13 Section 2.3 Effective Time 14 Section 2.4 Surviving Corpo |
|
| October 2, 2019 |
EX-99.2 Exhibit 99.2 Safe Harbor Statements Important Information For Investors And Stockholders This document does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to appropriate registration or qualification under the securities laws |
|
| October 2, 2019 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 1, 2019 Progenics Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-23143 13-3379479 (State or other jurisdiction of incorporation) (Co |
|
| October 2, 2019 |
EX-99.2 Exhibit 99.2 Safe Harbor Statements Important Information For Investors And Stockholders This document does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to appropriate registration or qualification under the securities laws |
|
| October 2, 2019 |
Amendment to the Bylaws of Progenics Pharmaceuticals, Inc. EX-3.2 Exhibit 3.2 AMENDMENT NO. 1 OF BY-LAWS OF PROGENICS PHARMACEUTICALS, INC. A DELAWARE CORPORATION (AMENDED AND RESTATED AS OF APRIL 1, 2019) October 1, 2019 The undersigned, the duly acting Secretary of the corporation, hereby certifies that: 1. The undersigned is the duly acting Secretary of PROGENICS PHARMACEUTICALS, INC., a Delaware corporation (the “corporation”). 2. Pursuant to a resolu |
|
| October 2, 2019 |
EX-99.1 Exhibit 99.1 Lantheus to Acquire Progenics to Form a Leading Precision Diagnostics Imaging and Therapeutics Company Highly Complementary Portfolio of Ultrasound and Radiopharmaceutical Diagnostics and Oncology Therapeutics Lantheus’ Proven Commercial, Manufacturing and Operational Excellence Well Positioned to Optimize the Combined Company’s Innovative Diagnostic and Radiopharmaceutical Po |
|
| October 2, 2019 |
PGNX / Progenics Pharmaceuticals, Inc. 425 - Merger Prospectus - 8-K 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 1, 2019 Progenics Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-23143 13-3379479 (State or other jurisdiction of incorporation) (Co |
|
| October 2, 2019 |
EX-2.1 Exhibit 2.1 Execution Version AGREEMENT AND PLAN OF MERGER AMONG LANTHEUS HOLDINGS, INC., PLATO MERGER SUB, INC. AND PROGENICS PHARMACEUTICALS, INC. DATED AS OF OCTOBER 1, 2019 Table of Contents Page Article I Defined Terms 2 Section 1.1 Certain Defined Terms 2 Article II The Merger 13 Section 2.1 The Merger 13 Section 2.2 Closing 13 Section 2.3 Effective Time 14 Section 2.4 Surviving Corpo |
|
| October 2, 2019 |
LNTH / Lantheus Holdings, Inc. 425 - Merger Prospectus - 8-K 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 1, 2019 LANTHEUS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36569 35-2318913 (State or other jurisdiction of incorporation) (Commis |
|
| October 2, 2019 |
EX-2.1 Exhibit 2.1 Execution Version AGREEMENT AND PLAN OF MERGER AMONG LANTHEUS HOLDINGS, INC., PLATO MERGER SUB, INC. AND PROGENICS PHARMACEUTICALS, INC. DATED AS OF OCTOBER 1, 2019 Table of Contents Page Article I Defined Terms 2 Section 1.1 Certain Defined Terms 2 Article II The Merger 13 Section 2.1 The Merger 13 Section 2.2 Closing 13 Section 2.3 Effective Time 14 Section 2.4 Surviving Corpo |
|
| October 2, 2019 |
EX-99.1 Exhibit 99.1 Lantheus to Acquire Progenics to Form a Leading Precision Diagnostics Imaging and Therapeutics Company Highly Complementary Portfolio of Ultrasound and Radiopharmaceutical Diagnostics and Oncology Therapeutics Lantheus’ Proven Commercial, Manufacturing and Operational Excellence Well Positioned to Optimize the Combined Company’s Innovative Diagnostic and Radiopharmaceutical Po |
|
| October 2, 2019 |
EX-99.2 Exhibit 99.2 Safe Harbor Statements Important Information For Investors And Stockholders This document does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to appropriate registration or qualification under the securities laws |
|
| October 2, 2019 |
PGNX / Progenics Pharmaceuticals, Inc. 425 - Merger Prospectus - 425 425 Filed by Progenics Pharmaceuticals, Inc. Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Progenics Pharmaceuticals, Inc. Commission File No.: 000 - 23143 Dear Progenics All- Today we announced that Progenics has entered into an agreement to be acquired by Lantheus, a global leader in the develop |
|
| October 2, 2019 |
LNTH / Lantheus Holdings, Inc. 425 - Merger Prospectus - 425 425 Filed by Lantheus Holdings, Inc. Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Progenics Pharmaceuticals, Inc. Commission File No.: 000 – 23143 Provided below is a transcript of a joint public conference call hosted by Lantheus Holdings, Inc. and Progenics Pharmaceuticals, Inc. on October 2, 2 |
|
| October 2, 2019 |
LNTH / Lantheus Holdings, Inc. 425 - Merger Prospectus - 425 425 Filed by Lantheus Holdings, Inc. Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Progenics Pharmaceuticals, Inc. Commission File No.: 000 – 23143 The following are screenshots of a website relating to the proposed transaction involving Lantheus Holdings, Inc. and Progenics Pharmaceuticals, Inc. |
|
| October 2, 2019 |
PGNX / Progenics Pharmaceuticals, Inc. 425 - Merger Prospectus - 425 425 Filed by Progenics Pharmaceuticals, Inc. Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Progenics Pharmaceuticals, Inc. Commission File No.: 000 - 23143 Provided below is a transcript of a joint public conference call hosted by Lantheus Holdings, Inc. and Progenics Pharmaceuticals, Inc. on Octo |
|
| October 2, 2019 |
PGNX / Progenics Pharmaceuticals, Inc. DFAN14A - - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of The Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide |
|
| September 30, 2019 |
PGNX / Progenics Pharmaceuticals, Inc. PRRN14A - - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN CONSENT STATEMENT SCHEDULE 14A INFORMATION Consent Statement Pursuant to Section 14(a) of The Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☒ Preliminary Consent Statement ☐ |
|
| September 25, 2019 |
PGNX / Progenics Pharmaceuticals, Inc. PREC14A - - FORM PREC14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Consent Revocation Statement Pursuant To Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| September 19, 2019 |
Exhibit 99.1 Velan launches consent solicitation TO RECONSTITUTE THE progenics BOARD WITH ITS FIVE HIGHLY-QUALIFIED, INDEPENDENT director nominees Believes its Five Completely Independent Nominees Would Bring Much-Needed Skill Sets and Drastically Improve the Board’s Strategic Oversight and Corporate Governance Failings Expresses Disappointment with Current Board’s Actions Following Stockholder Vo |
|
| September 19, 2019 |
Exhibit 99.3 POWER OF ATTORNEY Know all by these presents, that the undersigned hereby constitutes and appoints each of Balaji Venkataraman and Ryan Melkonian the undersigned’s true and lawful attorney-in-fact to take any and all action in connection with (i) the undersigned’s beneficial ownership of, or participation in a group with respect to, securities of Progenics Pharmaceuticals, Inc. (the “ |
|
| September 19, 2019 |
JOINT FILING AND SOLICITATION AGREEMENT Exhibit 99.2 JOINT FILING AND SOLICITATION AGREEMENT WHEREAS, certain of the undersigned are stockholders, direct or beneficial, of Progenics Pharmaceuticals, Inc., a Delaware corporation (the “Company”); WHEREAS, Velan Capital L.P., a Georgia limited partnership, Altiva Management Inc., a Nevada corporation, Balaji Venkataraman, Virinder Nohria, LTE Partners, LLC, a Delaware limited liability com |
|
| September 19, 2019 |
SC 13D/A 1 sc13da31227400209192019.htm AMENDMENT NO. 3 TO THE SCHEDULE 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 3)1 Progenics Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0. |
|
| September 18, 2019 |
PGNX / Progenics Pharmaceuticals, Inc. DEFA14A - - FORM DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Consent Revocation Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Consent Revocation Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2) |
|
| September 18, 2019 |
PGNX / Progenics Pharmaceuticals, Inc. DFAN14A - - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN CONSENT STATEMENT SCHEDULE 14A INFORMATION Consent Statement Pursuant to Section 14(a) of The Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Consent Statement ☐ C |
|
| September 18, 2019 |
PGNX / Progenics Pharmaceuticals, Inc. PREC14A - - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN CONSENT STATEMENT SCHEDULE 14A INFORMATION Consent Statement Pursuant to Section 14(a) of The Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☒ Preliminary Consent Statement ☐ C |
|
| August 28, 2019 |
Progenics Pharmaceuticals, Inc. Exhibit 99.1 Progenics Pharmaceuticals, Inc. One World Trade Center, 47th Floor, Suite J New York, NY 10007 Phone: (646) 975-2500 Fax: (646) 707-3626 www.progenics.com August 27, 2019 VIA E-MAIL Velan Capital LP c/o Bala Venkataraman Managing Partner 1055b Powers Place Alpharetta, GA 30009 Dear Bala, We are in receipt of your letter dated August 26, 2019. As we announced in the press release dated |
|
| August 28, 2019 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 27, 2019 Progenics Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-23143 13-3379479 (State or other jurisdiction of incorporation) (Commis |
|
| August 26, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 2)1 Progenics Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.0013 per share (Title of Class of Securities) 743187106 (CUSIP Number) Step |
|
| August 9, 2019 |
PROGENICS PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2019 FINANCIAL RESULTS AND BUSINESS UPDATE Exhibit 99.1 Progenics Pharmaceuticals, Inc. One World Trade Center 47th Floor, Suite J New York, New York 10007 (646) 975-2500 www.progenics.com PROGENICS PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2019 FINANCIAL RESULTS AND BUSINESS UPDATE ● Recorded First Revenues for AZEDRA®; CMS Grants New Technology Add-On Payment of Up to $98,150 per Therapeutic Dose for Inpatient Use of AZEDRA ● Enrollment C |
|
| August 9, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2019 Progenics Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-23143 13-3379479 (State or other jurisdiction of incorporation) (Commiss |
|
| August 9, 2019 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-23 |
|
| August 8, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2019 Progenics Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-23143 13-3379479 (State or other jurisdiction of incorporation) (Commiss |
|
| August 6, 2019 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2019 Progenics Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-23143 13-3379479 (State or other jurisdiction of incorporation) (Commiss |
|
| August 6, 2019 |
Exhibit 99.1 Progenics Pharmaceuticals, Inc. One World Trade Center 47th Floor, Suite J New York, New York 10007 (646) 975-2500 www.progenics.com Contact: Melissa Downs Investor Relations (646) 975-2533 [email protected] CMS Grants New Technology Add-On Payment for Inpatient Use of AZEDRA® (iobenguane I 131) Provides Additional Medicare Reimbursement up to 65% of the Cost of AZEDRA Prescribed f |
|
| August 5, 2019 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2019 Progenics Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-23143 13-3379479 (State or other jurisdiction of incorporation) (Commiss |
|
| August 5, 2019 |
Exhibit 99.1 Progenics Pharmaceuticals, Inc. One World Trade Center 47th Floor, Suite J New York, New York 10007 (646) 975-2500 www.progenics.com Contact: Melissa Downs Investor Relations (646) 975-2533 [email protected] Progenics Pharmaceuticals Completes Enrollment in Pivotal Phase 3 CONDOR Study of PyL for the Detection of Prostate Cancer Top-line Data Now Expected by Year End Reaches Alignm |
|
| July 22, 2019 |
PGNX / Progenics Pharmaceuticals, Inc. DFAN14A - - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of The Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide |
|
| July 22, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 11, 2019 Progenics Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-23143 13-3379479 (State or other jurisdiction of inco |
|
| July 18, 2019 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 17, 2019 Progenics Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-23143 13-3379479 (State or other jurisdiction of incorporation) (Commissi |
|
| July 18, 2019 |
Exhibit 99.1 Investor/Media Contact: Arthur Shannon [email protected] (514) 856-3855 (877) 281-6642 (toll free) COURT UPHOLDS THE VALIDITY AND DETERMINED ACTAVIS’ INFRINGEMENT OF PATENT PROTECTING RELISTOR® TABLETS BRIDGEWATER, N.J. and NEW YORK, N.Y., July 17, 2019 – Bausch Health Companies Inc. (NYSE/TSX: BHC) (“Bausch Health” or the “Company”) and Progenics Pharmaceuticals (NASDAQ |
|
| July 17, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 11, 2019 Progenics Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-23143 13-3379479 (State or other jurisdiction of incorporation) (Commissi |
|
| July 8, 2019 |
PGNX / Progenics Pharmaceuticals, Inc. DEFA14A - - FORM DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| July 8, 2019 |
PGNX / Progenics Pharmaceuticals, Inc. DFAN14A - - EXHIBIT 1 - FLYER begin 644 ex1dfan14a1227400207082019.pdf M)5!$1BTQ+C<-)>+CS],-"C<@,"!O8FH-/#PO3&EN96%R:7IE9" Q+TP@,3 T M,C0P."]/(#DO12 Q,#,X,#4V+TX@,2]4(#$P-#(Q,3C#;&DS^!8N< I%L9F#V/# I 229 M=9: 3;,#L=F7@]E[0.R<]V!V%)!D^ED*9K\$L4^G@^U=!B0975>!Q4$J/\GR M,C !W38-[!X&QF%(F=@TKH#$& ,<5N T*96YD , ^(L:.@T*96YD=4UHYKTI1+BBCD41E3%0N*8,2EY%D MY8K*(2BOE;')*&^09J26:5;>H99.RGND1BN/IB+K165U1GE"6I!F98WVRA>D MUJF@F485C+(%C0:KG |
|
| July 8, 2019 |
PGNX / Progenics Pharmaceuticals, Inc. DFAN14A - - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of The Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide |
|
| July 1, 2019 |
PGNX / Progenics Pharmaceuticals, Inc. DEFA14A - - FORM DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| July 1, 2019 |
PGNX / Progenics Pharmaceuticals, Inc. DFAN14A - - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of The Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide |
|
| June 28, 2019 |
PGNX / Progenics Pharmaceuticals, Inc. DEFA14A - - FORM DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| June 28, 2019 |
PGNX / Progenics Pharmaceuticals, Inc. DFAN14A - - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of The Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide |
|
| June 28, 2019 |
PGNX / Progenics Pharmaceuticals, Inc. DEFA14A - - FORM DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| June 28, 2019 |
PGNX / Progenics Pharmaceuticals, Inc. DFAN14A - - DFAN14A 1 dfan14a1227400206282019.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of The Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ |
|
| June 28, 2019 |
PGNX / Progenics Pharmaceuticals, Inc. DEFA14A - - FORM DEFA14A DEFA14A 1 prog20190627defa14a.htm FORM DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitte |
|
| June 25, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of The Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide |
|
| June 25, 2019 | ||
| June 24, 2019 |
PGNX / Progenics Pharmaceuticals, Inc. DEFA14A - - FORM DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| June 24, 2019 |
PGNX / Progenics Pharmaceuticals, Inc. DEFA14A - - FORM DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| June 24, 2019 |
PGNX / Progenics Pharmaceuticals, Inc. / FARALLON CAPITAL MANAGEMENT LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| June 21, 2019 |
Presentation to Institutional Shareholder Services Inc. and Glass, Lewis & Co. Exhibit 99.1 |
|
| June 21, 2019 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 20, 2019 Progenics Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-23143 13-3379479 (State or other jurisdiction of incorporation) (Commissi |
|
| June 21, 2019 |
PGNX / Progenics Pharmaceuticals, Inc. DEFA14A - - FORM DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| June 20, 2019 |
Regulation FD Disclosure, Financial Statements and Exhibits 8-K 1 prog201906198k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 20, 2019 Progenics Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-23143 13-3379479 (State or other jurisd |
|
| June 20, 2019 |
Exhibit 99.1 Progenics Pharmaceuticals, Inc. One World Trade Center 47th Floor, Suite J New York, New York 10007 (646) 975-2500 www.progenics.com Contact: Melissa Downs Investor Relations (646) 975-2533 [email protected] Progenics Pharmaceuticals to Initiate a Basket Trial by Year End to Support an Expanded Label for AZEDRA® (iobenguane I 131) in Multiple MIBG Avid Neuroendocrine Tumors NEW YOR |
|
| June 20, 2019 | ||
| June 20, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of The Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide |
|
| June 19, 2019 |
PGNX / Progenics Pharmaceuticals, Inc. DEFA14A - - FORM DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| June 17, 2019 |
PGNX / Progenics Pharmaceuticals, Inc. DFAN14A - - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of The Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide |
|
| June 13, 2019 |
PGNX / Progenics Pharmaceuticals, Inc. DEFA14A - - FORM DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| June 13, 2019 |
Exhibit 99.1 Progenics Pharmaceuticals, Inc. One World Trade Center 47th Floor, Suite J New York, New York 10007 (646) 975-2500 www.progenics.com Contact: Melissa Downs Investor Relations (646) 975-2533 [email protected] Progenics Pharmaceuticals Doses First Patient in Phase 2 Clinical Study of 1095 Radiotherapy for the Treatment of Metastatic Prostate Cancer NEW YORK, NY, June 13, 2019, – Prog |
|
| June 13, 2019 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2019 Progenics Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-23143 13-3379479 (State or other jurisdiction of incorporation) (Commissi |
|
| June 11, 2019 |
begin 644 ex1dfan14a1227400206112019.pdf M)5!$1BTQ+C4*)>+CS],*,R P(&]B:@H\/" *(" @+U1Y<&4@+U!A9V4*(" @ M+U!A%ZM'=F2&[?Q?;^"#TD5I\ID!L"< MJ52JXBNQ8R<^5'$.^V%DB9+*TFI-K>0H#D(QQ\<=#>[email protected] M](6^T!C>/7CU?OWKG[SL=LXMZ#.&[N':[J#?QW?'15[\=QNVG\"W M>U5/EV#\>Y6K<2C\V-/ 71N?;>Y]^G51>NOGP+Q$+K]LX7B&U,@'Q'@(+? M^X8 N8A?'3]M^MRO/.*-Z#ZOFNU/U2YL'U8[OSV^B&3GFTCKWH[?5^-\;8% MF]#6^ZXIL#&2U?;[OMOT;M@G]J |
|
| June 11, 2019 |
PGNX / Progenics Pharmaceuticals, Inc. DFAN14A - - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of The Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide |
|
| June 6, 2019 |
PGNX / Progenics Pharmaceuticals, Inc. DEFA14A - - FORM DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| June 6, 2019 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported):June 6, 2019 Progenics Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-23143 13-3379479 (State or other jurisdiction of incorporation) (Commission |
|
| June 6, 2019 |
Presentation to the Jefferies 2019 Healthcare Conference Exhibit 99.1 |
|
| June 5, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported):June 5, 2019 Progenics Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-23143 13-3379479 (State or other jurisdiction of incorporation) (Commission |
|
| June 4, 2019 |
PGNX / Progenics Pharmaceuticals, Inc. DFAN14A - - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of The Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide |
|
| June 3, 2019 |
PGNX / Progenics Pharmaceuticals, Inc. DEFA14A - - FORM DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| June 3, 2019 |
PGNX / Progenics Pharmaceuticals, Inc. DFRN14A - - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of The Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide |
|
| May 31, 2019 |
PGNX / Progenics Pharmaceuticals, Inc. DFAN14A - - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of The Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide |
|
| May 30, 2019 |
PGNX / Progenics Pharmaceuticals, Inc. DEFC14A - - FORM DEFC14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant To Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material under §240. |
|
| May 28, 2019 |
PGNX / Progenics Pharmaceuticals, Inc. PRER14A - - FORM PRER14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant To Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| May 28, 2019 |
PGNX / Progenics Pharmaceuticals, Inc. CORRESP - - O’Melveny & Myers LLP T: +1 212 326 2000 Times Square Tower F: +1 212 326 2061 Seven Times Square omm. |
|
| May 22, 2019 |
begin 644 ex1todfan14a12274002_052219.pdf M)5!$1BTQ+C,-)>+CS],-"C,R(# @;V)J#3P\+TQI;F5AV#7H^##RPP46SWG>=C6 @8T M8. A\T70TU0TLHR9I?&\H\CDP-#I"3@$Y3SZ(>PD\X=5# <5*I;8L@3YNH;% M=MQO?0%4>80#JDLR<[LLCR 32';:[,(+# Q*'1#0P"B!3#%P@"EF"PB/20.J M#.@NF 8&M@RX()C"YC4@$&-@RE$'TG) K H6$67@9^IAO,%\0U/!=,']QLT, MU2Q+^&RD)U@RY!QXWKBZP8:!.70)^PU% ?8&AD2F1D;F.0Q?&'BR/B@H^#E4 M-S PMA@:"Q!@ -_?<%0-"F5N9'-T7!E+T-A=&%L; |
|
| May 22, 2019 |
PGNX / Progenics Pharmaceuticals, Inc. DFAN14A - - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of The Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide |
